Antineoplastic Agents: Cytotoxic Agents: Antitumor Antibiotics
IBLEO1 “Bleocin injection” 15 mg/vial
適應症：頭、頸部癌（上顎癌、舌、口唇、咽喉、口腔等癌）皮膚癌（包括陰莖、陰囊及婦女外陰癌等）肺癌（原發性及轉移性扁平上皮癌）食道癌、惡性淋巴腫（細菌肉腫、淋巴肉腫、何杰金氏病）。
Usual dose:
Lymphoma, Hodgkin’s treatment: 10-20 U/m2 (0.25-0.5 U/kg) IV/IM/SC once or twice weekly; maitenance, following a 50% response, use a maintenance dose of 1 U once daily or 5 U once weekly IV/IM, max. total cumulative doses: 400 units.
Lymphoma, non-Hodgkin’s: 10-20 U/m2 (0.25-0.5 U/kg) IV/IM/SC once or twice weekly, max. total cumulative doses: 400 units.
Malignant pleural effusions: 60 U intrapleural injection single bolus dose dissolved in 50-100 ml NS, max. total cumulative doses: 400 units.
Testicular carcinoma: 10-20 U/m2 (0.25-0.5 U/kg) IV/IM/SC once or twice weekly, max. total cumulative doses: 400 units.
Squamous cell carcinoma 10-20 U/m2 (0.25-0.5 U/kg) IV/IM/SC once or twice weekly, max. total cumulative doses: 400 units.
Dose adjustment:
Renal impairment: 75% of dose for GFR 10-50 ml/min, 50% of dose for GFR < 10 ml/min.
Adverse effect:
Common: alopecia, chills, erythema, rash, hyperpigmentation, fever, nausea, vomiting, striae, vesiculation, skin tenderness, shivering, stomatitis, confusion, fever.
Serious: hypotension, vascular disorder, MI, CVA, Raynaud’s symdrome, myelosuppression, hepatotoxicity, nephrotoxicity, pneumonitis, possibly progressing to pulmonary fibrosis, pulmonary fibrosis (usually higher in elderly population and with > 400 units total dose), wheezing, idiosyncratic drug effect.